Andrew Paul Mazar Monopar Therapeutics (MNPR) insider trading activity
Andrew Paul Mazar is Chief Scientific Officer of Monopar Therapeutics. Currently has a direct ownership of 22,124 shares of MNPR, which is worth approximately $323,674. The most recent transaction as insider was on Mar 31, 2022, when has been sold 471 shares (Common Stock) at a price of $2.55 per share, resulting in proceeds of $1,201. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).
Shares Held (Direct Ownership)
22.1K
0%
3M change
0%
12M change
Total Value Held
$323,674
Andrew Paul Mazar Transaction History
APM
Andrew Paul Mazar
Chief Scientific Officer
Wilmette, IL